Endometrial Cancer
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) (4010-03-001 / ENGOT EN-6 / GOG-3031)
- Details
ClinicalTrials.gov ID:
NCT03981796
Diagnosis Type:
NA
USOR Number:
- Address
603 N Wilmot Rd, Suite 151
Tucson, AZ 85711
P: (520) 886-0206